🇺🇸 FDA
Pipeline program

Loncastuximab Tesirine

ADCT 402-202

Phase 2 small_molecule terminated

Quick answer

Loncastuximab Tesirine for Relapsed Follicular Lymphoma is a Phase 2 program (small_molecule) at ADC Therapeutics SA with 1 ClinicalTrials.gov record(s).

Program details

Company
ADC Therapeutics SA
Indication
Relapsed Follicular Lymphoma
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials